MetaCap

Relmada Therapeutics Inc. Company Profile

NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.62-0.49 (-15.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Relmada Therapeutics at a glance

Relmada Therapeutics Inc. (NASDAQ: RLMD) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Coral Gables, FL. Relmada Therapeutics is led by Dr. Sergio Traversa M.B.A., Pharm.D. and employs about 17 people. At a market capitalization of $279.5 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001553643, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Relmada Therapeutics do?

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Business description based on the company's public filings.

Company information

Legal name
Relmada Therapeutics Inc.
Ticker
NASDAQ: RLMD
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Sergio Traversa M.B.A., Pharm.D.
Employees
17
Headquarters
2222 Ponce de Leon Blvd., Coral Gables, FL, United States
Phone
786 629 1376
Market cap
$279.54M
SEC CIK
0001553643
Latest annual report
10-K · Mar 19, 2026

Companies similar to Relmada Therapeutics

RLMD peer companies
CompanyPrice% ChgMarket capCompare
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs RLMD
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs RLMD
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs RLMD
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs RLMD
EVMNEvommune Inc.7.04-2.76%$291.10Mvs RLMD
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs RLMD
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs RLMD
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs RLMD

Related